Adherex Technologies Inc.
TSX : AHX
AMEX : ADH

Adherex Technologies Inc.

August 03, 2005 09:02 ET

Adherex Initiates Two Additional Sites for Phase II Trial of ADH-1

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(CCNMatthews - Aug. 3, 2005) - Adherex Technologies Inc. (AMEX:ADH) (TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that it has initiated two additional sites for its Phase II clinical trial of ADH-1 (Exherin™): Princess Margaret Hospital in Toronto, Ontario, Canada and Jewish General Hospital in Montreal, Quebec, Canada. The study, which was launched in May 2005 at the Ottawa Regional Cancer Centre, is designed to evaluate the anti-tumor activity and tolerability of repeated doses of ADH-1 on an every three-week schedule in patients whose tumors express the molecular target N-cadherin.

"We are building additional momentum in the development of our lead biotechnology compound, ADH-1, with the addition of two more sites to our Canadian Phase II trial as planned. We have trials in Europe, the U.S. and Canada investigating three different dosing schedules and specific tumor types. Altogether, our Phase Ib/II and Phase II studies will provide important information regarding the optimal dose, dose schedule and tumor types for future Phase III ADH-1 trials," said William P. Peters, M.D., Ph.D., Chairman and CEO of Adherex. "Importantly, we now have a relationship with a major, multinational pharmaceutical company, GlaxoSmithKline, which has demonstrated interest in ADH-1 through its option to in-license the drug."

The Phase II trial is expected to enroll up to an aggregate of 60 patients and include eight different tumor types, including some more common cancers such as breast and lung as well as some cancers where anti-tumor activity was seen in the Phase I study, such as adrenocortical and esophageal. The trial size could be increased beyond 60 patients, depending on the level of anti-tumor activity noted. The Company expects the trial to conclude in the second half of 2006.

ADH-1 is a molecularly targeted anti-cancer drug that selectively targets N-cadherin, a protein that plays a major role in holding together and stabilizing cells that make up blood vessels and certain tumor cells. In the Phase I trial, ADH-1 was shown to be generally well tolerated and displayed evidence of anti-tumor activity in certain patients.

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in development including ADH-1 (Exherin™), eniluracil and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, a dihydropyrimidine dehydrogenase (DPD) inhibitor, is being developed to enhance the therapeutic value and effectiveness of 5-FU, one of the most widely-used oncology drugs in the world. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at www.adherex.com.

This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the clinical development plans of the Company, and the expected timing and results. We can provide no assurance that the clinical development will proceed as currently anticipated or that the expected timing or results will be realized. We are subject to the risks inherent in the biopharmaceutical industry, including the early stage of our product candidates, the uncertainties of clinical trials and regulatory review, and our history of losses. For a more detailed discussion of related risk factors, please refer to our public filings available at www.sedar.com and www.sec.gov.

Contact Information

  • Adherex Technologies Inc.
    Melissa Matson
    Director, Corporate Communications
    (919) 484-8484
    matsonm@adherex.com